Pharsight

Drug Patents Expiring in 2025

1. Abilify patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7115587

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(10 months from now)

US7550445

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(10 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 20 September, 2006

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR

How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage

ABILIFY family patents

Family Patents

2. Abilify Asimtufii patents expiration

ABILIFY ASIMTUFII's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338427 OTSUKA Methods for administering aripiprazole
Mar, 2025

(1 year, 17 days from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 27 April, 2023

Treatment: Use of aripiprazole in extended release injectable suspension

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ABILIFY ASIMTUFII family patents

Family Patents

3. Abilify Maintena Kit patents expiration

ABILIFY MAINTENA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338427 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Mar, 2025

(1 year, 17 days from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

4. Abraxane patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7820788

(Pediatric)

BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Apr, 2025

(1 year, 1 month from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage

ABRAXANE family patents

Family Patents

5. Acetadote patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399445 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(1 year, 5 months from now)

US8653061 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(1 year, 5 months from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage

ACETADOTE family patents

Family Patents

6. Adrenaclick patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297136 IMPAX Medicine injection devices and methods
Jan, 2025

(10 months from now)

US10166334 IMPAX Medicine injection apparatuses
Jan, 2025

(10 months from now)

US7621891 IMPAX Method and apparatus for delivering epinephrine
Feb, 2025

(11 months from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

ADRENACLICK family patents

Family Patents

7. Aemcolo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8529945 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 2 months from now)

US8486446 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 2 months from now)

US8741948 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 2 months from now)

US8263120 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 16, 2023
Generating Antibiotic Incentives Now (GAIN) Nov 16, 2028

Drugs and Companies using RIFAMYCIN SODIUM ingredient

NCE-1 date: 2027-11-17

Market Authorisation Date: 16 November, 2018

Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage

AEMCOLO family patents

Family Patents

8. Afinitor patents expiration

AFINITOR's oppositions filed in EPO
AFINITOR Litigations
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410131 NOVARTIS Cancer treatment
Nov, 2025

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2023

Drugs and Companies using EVEROLIMUS ingredient

Market Authorisation Date: 30 March, 2009

Treatment: Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib

Dosage: TABLET;ORAL

How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage

AFINITOR family patents

Family Patents

9. Airduo Digihaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(1 year, 3 days from now)

US9987229

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(1 year, 3 days from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(1 year, 2 months from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(1 year, 2 months from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 8 months from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

10. Aklief patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470871 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(1 year, 9 months from now)

US8227507 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(1 year, 9 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 4, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: 2023-10-05

Market Authorisation Date: 04 October, 2019

Treatment: Method of activating rargamma receptor; Topical treatment of acne vulgaris

Dosage: CREAM;TOPICAL

More Information on Dosage

AKLIEF family patents

Family Patents

11. Amitiza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748481 SUCAMPO PHARMA LLC Method for treating gastrointestinal disorder
Sep, 2025

(1 year, 6 months from now)

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 31 January, 2006

Treatment: Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome; Method for the long term treatment of chronic constipation in a human subject

Dosage: CAPSULE;ORAL

How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage

AMITIZA family patents

Family Patents

12. Amondys 45 patents expiration

AMONDYS 45's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9447415 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 4 months from now)

USRE48960 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 4 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 25, 2028
New Chemical Entity Exclusivity (NCE) Feb 25, 2026

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: 2025-02-25

Market Authorisation Date: 25 February, 2021

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by inducing exon-skipping of exon 45; Treatment of duchenne muscular...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AMONDYS 45 family patents

Family Patents

13. Amrix patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7387793 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants
Feb, 2025

(a year from now)

Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 01 February, 2007

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of AMRIX before it's drug patent expiration?
More Information on Dosage

AMRIX family patents

Family Patents

14. Anoro Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(1 year, 1 month from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(1 year, 1 month from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Jul, 2025

(1 year, 4 months from now)

US7439393

(Pediatric)

GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Nov, 2025

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

15. Antara (micronized) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8026281 LUPIN Treating metabolic syndrome with fenofibrate
Apr, 2025

(1 year, 1 month from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 30 November, 2004

Treatment: Treating severe hypertriglyceridemia; Treating primary hypercholesterolemia and mixed dyslipidemia

Dosage: CAPSULE;ORAL

How can I launch a generic of ANTARA (MICRONIZED) before it's drug patent expiration?
More Information on Dosage

ANTARA (MICRONIZED) family patents

Family Patents

16. Aptiom patents expiration

Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10675287 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 2 months from now)

US10695354 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 2 months from now)

US11364247 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 2 months from now)

US10702536 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(1 year, 2 months from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; Treatment of partial-onset seizures

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage

APTIOM family patents

Family Patents

17. Arcapta Neohaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(11 months from now)

Drugs and Companies using INDACATEROL MALEATE ingredient

Market Authorisation Date: 01 July, 2011

Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema

Dosage: POWDER;INHALATION

More Information on Dosage

ARCAPTA NEOHALER family patents

Family Patents

18. Arikayce Kit patents expiration

ARIKAYCE KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718189 INSMED INC Sustained release of antiinfectives
Jun, 2025

(1 year, 3 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents

19. Armonair Digihaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(1 year, 3 days from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(1 year, 2 months from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(1 year, 2 months from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 8 months from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

20. Astepro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Nov, 2025

(1 year, 8 months from now)

US9919050 MYLAN SPECIALITY LP Compositions comprising azelastine
Nov, 2025

(1 year, 8 months from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2008

Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage

ASTEPRO family patents

Family Patents

21. Astepro Allergy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Nov, 2025

(1 year, 8 months from now)

US9919050 BAYER HLTHCARE Compositions comprising azelastine
Nov, 2025

(1 year, 8 months from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage

ASTEPRO ALLERGY family patents

Family Patents

22. Auvi-q patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery
Jan, 2025

(10 months from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2025

(1 year, 23 days from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery
Apr, 2025

(1 year, 2 months from now)

US9149579 KALEO INC Devices, systems and methods for medicament delivery
Jul, 2025

(1 year, 4 months from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 10 August, 2012

Treatment: Method of treating allergic reaction via injection

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

AUVI-Q family patents

Family Patents

23. Baxdela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9539250 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(1 year, 7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8969569 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(1 year, 7 months from now)

US8648093 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(1 year, 7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 19, 2022
Generating Antibiotic Incentives Now (GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 2026-06-19

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults

Dosage: TABLET;ORAL

More Information on Dosage

BAXDELA family patents

Family Patents

24. Bepreve patents expiration

BEPREVE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784789 BAUSCH AND LOMB INC Aqueous liquid preparations and light-stabilized aqueous liquid preparations
Jan, 2025

(10 months from now)

Drugs and Companies using BEPOTASTINE BESILATE ingredient

Market Authorisation Date: 08 September, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of BEPREVE before it's drug patent expiration?
More Information on Dosage

BEPREVE family patents

Family Patents

25. Biktarvy patents expiration

BIKTARVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(1 year, 1 month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(1 year, 7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 7, 2028
M (M) Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 07 February, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents

26. Bosulif patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7919625 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(1 year, 9 months from now)

US7417148 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(1 year, 9 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 26, 2030
New Product (NP) Sep 26, 2026
Pediatric Exclusivity (PED) Mar 26, 2027

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Market Authorisation Date: 26 September, 2023

Treatment: A method of treating patients 1 year of age and older with chronic phase ph+ cml, newly-diagnosed or resistant or intolerant to prior therapy; A method of treating patients with accelerated, or blast ...

Dosage: CAPSULE;ORAL

How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage

BOSULIF family patents

Family Patents

27. Breo Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7439393 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7439393

(Pediatric)

GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Nov, 2025

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 13, 2026
New Strength (NS) May 13, 2026
Pediatric Exclusivity (PED) Nov 13, 2026

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including bronchitis and/or emphysema; Indicated fo...

Dosage: POWDER;INHALATION

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

28. Brilinta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46276

(Pediatric)

ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Apr, 2025

(1 year, 2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) May 9, 2025
Pediatric Exclusivity (PED) Nov 9, 2025

Drugs and Companies using TICAGRELOR ingredient

Market Authorisation Date: 20 July, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents

29. Brisdelle patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(1 year, 2 months from now)

Drugs and Companies using PAROXETINE MESYLATE ingredient

Market Authorisation Date: 28 June, 2013

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of BRISDELLE before it's drug patent expiration?
More Information on Dosage

BRISDELLE family patents

Family Patents

30. Brixadi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545832 BRAEBURN Lipid depot formulations
Jun, 2025

(1 year, 3 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 23, 2026

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 23 May, 2023

Treatment: A method of delivery of a bioactive agent by subcutaneous injection. a method of treatment of a human for addiction

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BRIXADI family patents

Family Patents

31. Bydureon patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(1 year, 1 month from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(1 year, 1 month from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(1 year, 1 month from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(1 year, 4 months from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 7 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 7 months from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 7 months from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 10 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of ...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

Family Patents

32. Bydureon Bcise patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(1 year, 1 month from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(1 year, 1 month from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(1 year, 1 month from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(1 year, 4 months from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 7 months from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 7 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(1 year, 7 months from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 10 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of ...

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

33. Cabenuva Kit patents expiration

CABENUVA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(1 year, 1 month from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
New Dosing Schedule (D) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

CABENUVA KIT family patents

Family Patents

34. Chlorhexidine Gluconate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7717889 SAGE PRODS Disinfectant delivery system and method of providing alcohol free disinfection
Feb, 2025

(1 year, 1 day from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Market Authorisation Date: 25 April, 2005

Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection

Dosage: CLOTH;TOPICAL

More Information on Dosage

CHLORHEXIDINE GLUCONATE family patents

Family Patents

35. Ciprodex patents expiration

CIPRODEX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846650 NOVARTIS Method of treating middle ear infections
Jun, 2025

(1 year, 3 months from now)

Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient

Market Authorisation Date: 18 July, 2003

Treatment: Treatment of acute otitis media

Dosage: SUSPENSION/DROPS;OTIC

How can I launch a generic of CIPRODEX before it's drug patent expiration?
More Information on Dosage

CIPRODEX family patents

Family Patents

36. Combivent Respimat patents expiration

COMBIVENT RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 2 months from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage

COMBIVENT RESPIMAT family patents

Family Patents

37. Combogesic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10532036 AFT PHARMS LTD Combination composition
Sep, 2025

(1 year, 6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 1, 2026

Drugs and Companies using ACETAMINOPHEN; IBUPROFEN ingredient

Market Authorisation Date: 01 March, 2023

Treatment: A method of treating mild to moderate acute pain in adults by administering 975-1000 mg of acetaminophen and 292.5-300 mg of ibuprofen in a single administration

Dosage: TABLET;ORAL

More Information on Dosage

COMBOGESIC family patents

Family Patents

38. Complera patents expiration

COMPLERA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(1 year, 1 month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8841310 GILEAD SCIENCES INC Combinations of a pyrimidine containing NNRTI with RT inhibitors
Dec, 2025

(1 year, 9 months from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 10 August, 2011

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage

COMPLERA family patents

Family Patents

39. Contrave patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7375111 NALPROPION Compositions for affecting weight loss
Mar, 2025

(1 year, 28 days from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

40. Coreg Cr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101209 WOODWARD Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
Sep, 2025

(1 year, 6 months from now)

Drugs and Companies using CARVEDILOL PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2006

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of COREG CR before it's drug patent expiration?
More Information on Dosage

COREG CR family patents

Family Patents

41. Cresemba patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6812238 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2025

(1 year, 8 months from now)

US10812238 ASTELLAS Configurable reference signals
Oct, 2025

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 8, 2030
New Chemical Entity Exclusivity (NCE) Mar 6, 2020
New Patient Population (NPP) Dec 8, 2026
Pediatric Exclusivity (PED) Jun 8, 2031
Generating Antibiotic Incentives Now (GAIN) Sep 6, 2027

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: 2030-06-08

Market Authorisation Date: 06 March, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

CRESEMBA family patents

Family Patents

42. Daytrana patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(1 year, 7 months from now)

US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(1 year, 7 months from now)

US9668981 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic based polymers
Oct, 2025

(1 year, 7 months from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 06 April, 2006

Treatment: Method for transdermally delivering a drug to a user in need thereof

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of DAYTRANA before it's drug patent expiration?
More Information on Dosage

DAYTRANA family patents

Family Patents

43. Defencath patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7696182 CORMEDIX Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
May, 2025

(1 year, 2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 15, 2028
Generating Antibiotic Incentives Now (GAIN) Nov 15, 2033

Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient

NCE-1 date: 2032-11-15

Market Authorisation Date: 15 November, 2023

Treatment: A catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter

Dosage: SOLUTION;N/A

More Information on Dosage

DEFENCATH family patents

Family Patents

44. Descovy patents expiration

DESCOVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(1 year, 1 month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(1 year, 7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 7, 2029

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 04 April, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DESCOVY before it's drug patent expiration?
More Information on Dosage

DESCOVY family patents

Family Patents

45. Differin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579377 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Feb, 2025

(11 months from now)

Drugs and Companies using ADAPALENE ingredient

Market Authorisation Date: 19 June, 2007

Treatment: Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

How can I launch a generic of DIFFERIN before it's drug patent expiration?
More Information on Dosage

DIFFERIN family patents

Family Patents

46. Diprivan patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476010

(Pediatric)

FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Jun, 2025

(1 year, 3 months from now)

Drugs and Companies using PROPOFOL ingredient

Market Authorisation Date: 02 October, 1989

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DIPRIVAN before it's drug patent expiration?
More Information on Dosage

DIPRIVAN family patents

Family Patents

47. Dojolvi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186344 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Jul, 2025

(1 year, 4 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 30, 2027
New Chemical Entity Exclusivity (NCE) Jun 30, 2025

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: 2024-06-30

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID;ORAL

More Information on Dosage

DOJOLVI family patents

Family Patents

48. Duaklir Pressair patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46417 ASTRAZENECA Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
Feb, 2025

(11 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination (NC) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

DUAKLIR PRESSAIR family patents

Family Patents

49. Durysta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673341 ALLERGAN INC Intraocular pressure reduction with intracameral bimatoprost implants
Feb, 2025

(11 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

Family Patents

50. Duzallo patents expiration

Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8003681 IRONWOOD PHARMS INC 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
Aug, 2025

(1 year, 5 months from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

DUZALLO family patents

Family Patents

51. Edarbi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(10 months from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

Market Authorisation Date: 25 February, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of EDARBI before it's drug patent expiration?
More Information on Dosage

EDARBI family patents

Family Patents

52. Edarbyclor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(10 months from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage

EDARBYCLOR family patents

Family Patents

53. Edurant patents expiration

EDURANT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(1 year, 1 month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125879

(Pediatric)

JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Oct, 2025

(1 year, 7 months from now)

Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 20 May, 2011

Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive patients with hiv-1 rna less than or equal to 100,000 at the start of thearpy; In combination wi...

Dosage: TABLET;ORAL

More Information on Dosage

EDURANT family patents

Family Patents

54. Embeda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685444 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Jul, 2025

(1 year, 4 months from now)

US8685443 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Jul, 2025

(1 year, 4 months from now)

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of EMBEDA before it's drug patent expiration?
More Information on Dosage

EMBEDA family patents

Family Patents

55. Entresto patents expiration

ENTRESTO's oppositions filed in EPO
ENTRESTO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2025

(10 months from now)

US8101659

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2025

(1 year, 4 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Feb 16, 2024

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

56. Epanova patents expiration

EPANOVA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9012501 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(11 months from now)

US9132112 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(11 months from now)

US8383678 ASTRAZENECA Type a gelatin capsule containing PUFA in free acid form
Feb, 2025

(11 months from now)

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

Market Authorisation Date: 05 May, 2014

Treatment: Treatment of hypertriglyceridemia

Dosage: CAPSULE;ORAL

More Information on Dosage

EPANOVA family patents

Family Patents

57. Epi E Z Pen Jr patents expiration

EPI E Z PEN JR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8870827 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(1 year, 6 months from now)

US7449012 MYLAN SPECIALITY LP Automatic injector
Sep, 2025

(1 year, 6 months from now)

US9586010 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(1 year, 6 months from now)

US7794432 MYLAN SPECIALITY LP Automatic injector with kickback attenuation
Sep, 2025

(1 year, 6 months from now)

US8048035 MYLAN SPECIALITY LP Automatic injector with needle cover
Sep, 2025

(1 year, 6 months from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 22 December, 1987

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

How can I launch a generic of EPI E Z PEN JR before it's drug patent expiration?
More Information on Dosage

EPI E Z PEN JR family patents

Family Patents

58. Epiduo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7820186 GALDERMA LABS LP Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
Nov, 2025

(1 year, 8 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 08 December, 2008

Treatment: NA

Dosage: GEL;TOPICAL

How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage

EPIDUO family patents

Family Patents

59. Erivedge patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9790183 GENENTECH Pyridyl inhibitors of hedgehog signalling
Sep, 2025

(1 year, 6 months from now)

Drugs and Companies using VISMODEGIB ingredient

Market Authorisation Date: 30 January, 2012

Treatment: Method of using vismodegib to treat basal cell carcinoma

Dosage: CAPSULE;ORAL

More Information on Dosage

ERIVEDGE family patents

Family Patents

60. Evzio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery
Jan, 2025

(10 months from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2025

(1 year, 23 days from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery
Apr, 2025

(1 year, 2 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

Family Patents

61. Evzio (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery
Jan, 2025

(10 months from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2025

(1 year, 23 days from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery
Apr, 2025

(1 year, 2 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

62. Exondys 51 patents expiration

EXONDYS 51's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10781451 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 4 months from now)

US9018368 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47751 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 4 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

Market Authorisation Date: 19 September, 2016

Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Treatment of duchenne muscular dystrophy (dmd) in patients having a mutatio...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

EXONDYS 51 family patents

Family Patents

63. Exxua patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7538116 FABRE KRAMER Treatment of sexual disorders
Sep, 2025

(1 year, 6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2028

Drugs and Companies using GEPIRONE HYDROCHLORIDE ingredient

NCE-1 date: 2027-09-23

Market Authorisation Date: 22 September, 2023

Treatment: Treatment of subjects with major depression with sexual dysfunction caused by either major depression or prior treatments, or treatment of subjects with major depression without the risk of sexual dys...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

EXXUA family patents

Family Patents

64. Fanapt patents expiration

FANAPT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138432 VANDA PHARMS INC Methods for the administration of iloperidone
Sep, 2025

(1 year, 7 months from now)

Drugs and Companies using ILOPERIDONE ingredient

Market Authorisation Date: 06 May, 2009

Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine

Dosage: TABLET;ORAL

How can I launch a generic of FANAPT before it's drug patent expiration?
More Information on Dosage

FANAPT family patents

Family Patents

65. Farxiga patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(1 year, 1 month from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(1 year, 1 month from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(1 year, 4 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Apr 30, 2024
M (M) May 8, 2026

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

66. Femtrace patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572779 APIL Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Oct, 2025

(1 year, 7 months from now)

Drugs and Companies using ESTRADIOL ACETATE ingredient

Market Authorisation Date: 20 August, 2004

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage

FEMTRACE family patents

Family Patents

67. Folotyn patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8299078 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(1 year, 3 months from now)

US7622470 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(1 year, 3 months from now)

Drugs and Companies using PRALATREXATE ingredient

Market Authorisation Date: 24 September, 2009

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of FOLOTYN before it's drug patent expiration?
More Information on Dosage

FOLOTYN family patents

Family Patents

68. Forteo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7517334 LILLY Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose
Mar, 2025

(1 year, 27 days from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Nov 16, 2023

Drugs and Companies using TERIPARATIDE ingredient

Market Authorisation Date: 26 November, 2002

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of FORTEO before it's drug patent expiration?
More Information on Dosage

FORTEO family patents

Family Patents

69. Gattex Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968655 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9592273 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9539310 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9974835 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9555079 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9987334 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9060992 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9981016 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9968656 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9987335 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9592274 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9974837 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9981014 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US7847061 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9545434 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9572867 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9993528 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9968658 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

US9545435 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 16, 2026

Drugs and Companies using TEDUGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 21 December, 2012

Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

GATTEX KIT family patents

Family Patents

70. Genosyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609028 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 5 months from now)

US9956373 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 5 months from now)

US8821801 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 5 months from now)

US8226916 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 5 months from now)

US9522249 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 5 months from now)

US11291793 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 5 months from now)

US11383059 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 5 months from now)

US10124142 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 5 months from now)

US10814092 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Oct, 2025

(1 year, 7 months from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: A method of delivering nitric oxide to a patient

Dosage: GAS;INHALATION

More Information on Dosage

GENOSYL family patents

Family Patents

71. Genosyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11554241 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 5 months from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: A method of delivering nitric oxide to a patient

Dosage: GAS;INHALATION

More Information on Dosage

GENOSYL family patents

Family Patents

72. Genvoya patents expiration

GENVOYA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(1 year, 1 month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(1 year, 7 months from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 05 November, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage

GENVOYA family patents

Family Patents

73. Givlaari patents expiration

GIVLAARI Litigations
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9150605 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Aug, 2025

(1 year, 6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 20, 2024
Orphan Drug Exclusivity (ODE) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 2023-11-21

Market Authorisation Date: 20 November, 2019

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GIVLAARI family patents

Family Patents

74. Glumetza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7780987 SANTARUS INC Controlled release dosage forms
Mar, 2025

(1 year, 25 days from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 03 June, 2005

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of GLUMETZA before it's drug patent expiration?
More Information on Dosage

GLUMETZA family patents

Family Patents

75. Glyxambi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(1 year, 8 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Market Authorisation Date: 30 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage

GLYXAMBI family patents

Family Patents

76. Gocovri patents expiration

Can you believe GOCOVRI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889740 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(1 year, 8 months from now)

US8895614 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(1 year, 8 months from now)

US8895618 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(1 year, 8 months from now)

US8895617 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(1 year, 8 months from now)

US8796337 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(1 year, 8 months from now)

US8895616 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(1 year, 8 months from now)

US8895615 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 24, 2024

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of GOCOVRI before it's drug patent expiration?
More Information on Dosage

GOCOVRI family patents

Family Patents

77. Horizant patents expiration

HORIZANT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6818787 AZURITY Prodrugs of GABA analogs, compositions and uses thereof
Apr, 2025

(1 year, 1 month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8686034 AZURITY Crystalline form of γ-aminobutyric acid analog
Jan, 2025

(10 months from now)

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

Market Authorisation Date: 06 April, 2011

Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; Management of postherpetic neuralgia (phn) in adults

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage

HORIZANT family patents

Family Patents

78. Hysingla Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11844865 PURDUE PHARMA LP Abuse-proofed oral dosage form
Feb, 2025

(11 months from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HYSINGLA ER before it's drug patent expiration?
More Information on Dosage

HYSINGLA ER family patents

Family Patents

79. Incivek patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7820671 VERTEX PHARMS Peptidomimetic protease inhibitors
Feb, 2025

(11 months from now)

Drugs and Companies using TELAPREVIR ingredient

Market Authorisation Date: 23 May, 2011

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

INCIVEK family patents

Family Patents

80. Incruse Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7498440 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Apr, 2025

(1 year, 1 month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Apr, 2025

(1 year, 1 month from now)

US8183257 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Jul, 2025

(1 year, 4 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

Market Authorisation Date: 30 April, 2014

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage

INCRUSE ELLIPTA family patents

Family Patents

81. Injectafer patents expiration

INJECTAFER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7612109 AM REGENT Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes
Feb, 2025

(11 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) May 31, 2026
New Patient Population (NPP) Nov 19, 2024
New Strength (NS) Apr 28, 2024

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of INJECTAFER before it's drug patent expiration?
More Information on Dosage

INJECTAFER family patents

Family Patents

82. Inlyta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6534524 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Apr, 2025

(1 year, 2 months from now)

Drugs and Companies using AXITINIB ingredient

Market Authorisation Date: 27 January, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage

INLYTA family patents

Family Patents

83. Intermezzo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252809 PURDUE PHARMA Compositions for treating insomnia
Feb, 2025

(11 months from now)

US7682628 PURDUE PHARMA Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
Feb, 2025

(11 months from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 23 November, 2011

Treatment: Method for treating insomnia

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of INTERMEZZO before it's drug patent expiration?
More Information on Dosage

INTERMEZZO family patents

Family Patents

84. Invokamet patents expiration

INVOKAMET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(1 year, 1 month from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2014

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage

INVOKAMET family patents

Family Patents

85. Invokamet Xr patents expiration

INVOKAMET XR's oppositions filed in EPO